Hemenway Trust Co LLC Acquires 1,213 Shares of Moderna, Inc. (NASDAQ:MRNA)

Hemenway Trust Co LLC lifted its holdings in Moderna, Inc. (NASDAQ:MRNA) by 20.1% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 7,243 shares of the company’s stock after acquiring an additional 1,213 shares during the quarter. Hemenway Trust Co LLC’s holdings in Moderna were worth $772,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in MRNA. Ogorek Anthony Joseph NY ADV bought a new stake in Moderna during the 4th quarter valued at $27,000. Arlington Trust Co LLC raised its holdings in Moderna by 4,833.3% in the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after purchasing an additional 290 shares in the last quarter. Westside Investment Management Inc. bought a new position in Moderna in the 1st quarter worth $32,000. Rise Advisors LLC raised its holdings in Moderna by 953.3% in the 1st quarter. Rise Advisors LLC now owns 316 shares of the company’s stock worth $34,000 after purchasing an additional 286 shares in the last quarter. Finally, UMB Bank n.a. raised its holdings in Moderna by 121.8% in the 1st quarter. UMB Bank n.a. now owns 366 shares of the company’s stock worth $39,000 after purchasing an additional 201 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna Stock Performance

MRNA traded up $5.38 during midday trading on Thursday, hitting $122.82. 4,162,666 shares of the company traded hands, compared to its average volume of 4,133,406. The company has a quick ratio of 3.91, a current ratio of 4.03 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $47.07 billion, a PE ratio of -7.84 and a beta of 1.66. The company’s 50-day moving average is $135.36 and its 200 day moving average is $113.67. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $170.47.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The business had revenue of $167.00 million for the quarter, compared to analysts’ expectations of $93.26 million. During the same quarter in the prior year, the business earned $0.19 EPS. The business’s revenue for the quarter was down 91.0% compared to the same quarter last year. On average, research analysts expect that Moderna, Inc. will post -7.46 EPS for the current year.

Insider Transactions at Moderna

In other Moderna news, CFO James M. Mock sold 648 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $162.47, for a total transaction of $105,280.56. Following the sale, the chief financial officer now owns 5,726 shares in the company, valued at approximately $930,303.22. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Moderna news, President Stephen Hoge sold 255 shares of the stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $120.96, for a total transaction of $30,844.80. Following the completion of the sale, the president now directly owns 1,486,508 shares of the company’s stock, valued at approximately $179,808,007.68. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO James M. Mock sold 648 shares of the stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $162.47, for a total transaction of $105,280.56. Following the sale, the chief financial officer now directly owns 5,726 shares of the company’s stock, valued at $930,303.22. The disclosure for this sale can be found here. Insiders have sold 381,239 shares of company stock worth $52,996,537 in the last quarter. Company insiders own 15.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on MRNA shares. Royal Bank of Canada upped their price objective on shares of Moderna from $135.00 to $160.00 and gave the stock an “outperform” rating in a report on Monday, June 3rd. Canaccord Genuity Group upped their price objective on shares of Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a report on Friday, May 3rd. William Blair reaffirmed a “market perform” rating on shares of Moderna in a research report on Thursday, June 27th. Oppenheimer upped their target price on shares of Moderna from $163.00 to $179.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 12th. Finally, UBS Group upped their target price on shares of Moderna from $143.00 to $151.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $134.02.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.